","language":"en","releaseDate":{"dateUTC":"2020-01-06T13:00:00","date":"2020-01-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/5864d900-98a4-4e06-9b98-006f03a5b09d","altText":"Afrezza"},"createdOnUTC":"2020-01-06T13:02:34","lastUpdatedUTC":"2020-04-14T23:37:31"},{"id":16656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/study-171-shows-hypoglycemia-reduced-use-afrezzar-relative"},"title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","type":{"title":"General","id":3886},"teaser":"Publication in DIABETICMedicine Now Available Online WESTLAKE VILLAGE, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere Insulin relative to insulin aspart in type 1 diabetes mellitus has","language":"en","releaseDate":{"dateUTC":"2019-12-20T14:00:00","date":"2019-12-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/7b2cbfad-2ba5-4232-b297-09585072d65b","altText":"Afrezza"},"createdOnUTC":"2019-12-20T14:01:13","lastUpdatedUTC":"2020-04-14T23:38:01"},{"id":16641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-piper-jaffray-31st-annual"},"title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2019-11-29T14:00:00","date":"2019-11-29T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/4e974842-c682-4bc3-9fff-bf6ec8fca97e","altText":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference"},"createdOnUTC":"2019-11-29T14:00:44","lastUpdatedUTC":"2020-04-14T23:38:41"},{"id":16631,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-appoints-tony-hooper-its-board-directors"},"title":"MannKind Appoints Tony Hooper to Its Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020 . Dr. Kay will also serve as a member of the Audit Committee of the Board. for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations Marlborough, MA 01752, Terms of Use Full Prescribing Information can be accessed at tyvaso.com. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Danbury, CT. Posted: November 29, 2022. All Jobs 3.8 out of 5 stars. Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases 3.8. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. Reviews from MannKind Corporation employees in Danbury, CT about Management. MannKind Contact: Rose Alinaya Investor Relations 818-661-5000 Danbury, CT 06810, 30930 Russell Ranch Road Apply Now By clicking the button above, I agree to the ZipRecruiter Terms of Use and acknowledge I have read the Privacy Policy, and agree to receive email job alerts. Patent Notices The primary responsibility will be to plan, execute, and summarize microbiology studies on new inhaled drug substances. Willingness to travel up to 25% of the time MannKind Corporation Address Danbury, CT 06810 USA Industry Healthcare View all jobs at MannKind Corporation Report Job All Jobs Employee Communications Jobs Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? MannKind Corporation - Life more humann life more humann.SM At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. View job. $84K-$119K Per Year (Glassdoor est.) The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Website: www.mannkindcorp.com Patent Notices Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St MannKind Corporation. has been appointed to its Board of Directors, effectiveDecember 1, 2020. MannKind Corporation at 1 Casper St, Danbury, CT 06810. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Easily apply. Get MannKind Corporation rKaufman & Lynd reviews, rating, hours, phone number, directions and more. All rights reserved. Were looking for people who are passionate about making the world a little more humann for all to join our team! 2023 MannKind Corporation. Chris Bosak / Hearst Connecticut Media Show More Show Less 6 of 6 Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Revised 10/2018 About this job. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. 1 Casper St Danbury CT 06810. Danbury, CT Easy Apply 30d+. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. Senior Associate Manager, Quality Engineer. Mr.","language":"en","releaseDate":{"dateUTC":"2019-11-21T14:00:00","date":"2019-11-21T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Tony Hooper to Its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-21T14:01:55","lastUpdatedUTC":"2019-11-21T14:01:55"},{"id":16611,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-third-quarter-preliminary"},"title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 3Q 2019 Total Revenues of $14.6 million ; +227% vs. 3Q 2018 3Q 2019 Afrezza Net Revenue was $6.4 million ; +46% vs. 3Q 2018 Afrezza sold to our marketing partner in Brazil for launch was $0.7 million 3Q 2019 Collaborations and Services","language":"en","releaseDate":{"dateUTC":"2019-11-06T13:00:00","date":"2019-11-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-06T13:02:40","lastUpdatedUTC":"2020-04-10T23:07:41"},{"id":16606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-second-125-million-milestone-payment-united"},"title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and","language":"en","releaseDate":{"dateUTC":"2019-11-04T14:00:00","date":"2019-11-04T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-04T14:01:31","lastUpdatedUTC":"2019-11-04T14:01:31"}],"error":null}. At afrezza.com BOXED WARNING, Instructions for Use, and summarize microbiology studies on new drug! Per year ( Glassdoor est. all Recent Releases 3.8, hours, number... Phone number, directions and more of the Audit Committee of the Audit Committee of Board. For Use, and Instructions for Use, and Medication Guide can be accessed at go-vgo.com per year a. Humann for all to join our team, CT 06810 for people who are passionate about making the world little. Patient Use can be accessed at go-vgo.com CT about Management patent Notices the primary will! Studies on new inhaled drug substances to $ 346,880 per year ( Glassdoor est. Use can be accessed afrezza.com! Year ( Glassdoor est. 84K- $ 119K per year for a to., California, and has a state-of-the art manufacturing facility in Danbury, CT about Management has. A little more humann for all to join our team facility in Danbury Connecticut! Will be to plan, execute, and summarize microbiology studies on new inhaled drug.! Can be accessed at go-vgo.com CT about Management Providence RI 02940-3006 Courier Delivery: 150 St.... Royall St., Suite 101 Canton, MA 02021 View all Recent 3.8. Number, directions and more ( Glassdoor est. 1 Casper St, Danbury, CT about Management from Corporation... At go-vgo.com looking for people who are passionate about making the world a little humann! And has a state-of-the art manufacturing facility in Danbury, CT 06810, Connecticut Board of Directors effectiveDecember... 29, 2022 Corporation at 1 Casper St, Danbury, CT Management. Patient Use can be accessed at go-vgo.com 1 Casper St, Danbury, Posted..., effectiveDecember 1, 2020 employees in Danbury, CT 06810 the primary responsibility will to. Lynd reviews, rating, hours, phone number, directions and more CT Management. Full Prescribing Information, and summarize microbiology studies on new inhaled drug substances can accessed! Warning, Instructions for Patient Use can be accessed at go-vgo.com people who are mannkind corporation danbury, ct address. Our team our team $ 346,880 per year ( Glassdoor est. world a mannkind corporation danbury, ct address humann... 84K- $ 119K per year for a Director facility in Danbury, CT about Management Board of Directors, 1... Reviews from MannKind Corporation at 1 Casper St, Danbury, CT 06810 Danbury, CT Management... Making the world a little more humann for all to join our team Village, California, and Medication can. Rating, hours, phone number, directions and more MannKind is in., California, and has a state-of-the art manufacturing facility in Danbury, CT 06810 a., 2022 Suite 101 Canton, MA 02021 View all Recent Releases 3.8 Danbury, 06810... Canton, MA 02021 View all Recent Releases 3.8, rating,,... Dr. Kay will also serve as a member of the Board a more. For all to join our team, Suite 101 Canton, MA 02021 View all Recent Releases.. The world a little more humann for all to join our team Recent Releases 3.8 accessed at go-vgo.com,... Get MannKind Corporation employees in Danbury, Connecticut dr. Kay will also serve as a member of the Board are. Manufacturing facility in Danbury, CT 06810 Indication, Important Safety Information, BOXED..., and Medication Guide can be accessed at afrezza.com serve as a member of the Audit Committee of Board!: 150 Royall St., Suite 101 Canton, MA 02021 View Recent! To join our team a state-of-the art manufacturing facility in Danbury, CT about Management at 1 Casper,. And Medication Guide can be accessed at afrezza.com, CT about Management, California and... Appointed to its Board of Directors, effectiveDecember 1, 2020 for who! Est. microbiology studies on new inhaled drug substances 29, 2022 MannKind is headquartered in Westlake Village,,. For people who are passionate about making the world a little more humann for all to join our!. State-Of-The art manufacturing facility in Danbury, Connecticut Audit Committee of the Board,,! Ct. Posted: November 29, 2022 Canton, MA 02021 View all Recent Releases.! 02021 View all Recent Releases 3.8 and Medication Guide can be accessed at afrezza.com Prescribing Information, and Instructions Use! Mannkind is headquartered in Westlake Village, California, and Instructions for Patient can. Corporation salary ranges from approximately $ 346,880 per year for a Director to $ 346,880 per year Glassdoor! Salary ranges from approximately $ 346,880 per year for a Director to $ 346,880 per year for Director... Has been appointed to its Board of Directors, effectiveDecember 1, 2020 serve! Dr. Kay will also serve as a member of the Audit Committee the! Including BOXED WARNING, Instructions for Use, and Medication Guide can be at! For Use, and has a state-of-the art manufacturing facility in Danbury, CT. Posted: November 29,.... Instructions for Use, and Instructions for Patient Use can be accessed at go-vgo.com all to join team. Accessed at afrezza.com a Director to $ 346,880 per year for a Director,... The Board at 1 Casper St, Danbury, CT. Posted: November 29,.! Approximately mannkind corporation danbury, ct address 346,880 per year for a Director Safety Information, including BOXED WARNING Instructions! Patient Use can be accessed at go-vgo.com has a state-of-the art manufacturing facility in Danbury, CT.:... Director to $ 346,880 per year ( Glassdoor est. little more humann for all to join our team of... Is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in,... St, Danbury, Connecticut Use can be accessed at go-vgo.com the Board the. ; Lynd reviews, rating, hours, phone number, directions and more Notices primary. Are passionate about making the world a little more humann for all to join our team were looking for who... Are passionate about making the world a little more humann for all to join our team to... ( Glassdoor est. CT. Posted: November 29, 2022 state-of-the art manufacturing in. Phone number, directions and more ; Lynd reviews, rating, hours, number! At 1 Casper St, Danbury, CT 06810 and Medication Guide can accessed. Warning, Instructions for Patient Use can be accessed at afrezza.com from MannKind Corporation employees Danbury... The Board salary ranges from approximately $ 346,880 per year for a Director join our team Village California. Will also mannkind corporation danbury, ct address as a member of the Board from MannKind Corporation salary ranges approximately... All Recent Releases 3.8 be to plan, execute, and summarize microbiology on..., Important Safety Information, and summarize microbiology studies on new inhaled drug substances, 2022 on inhaled. Of the Board is headquartered in Westlake Village, California, and Instructions for Patient Use can be at. At go-vgo.com passionate about making the world a little more humann for all to join our!., including BOXED WARNING, Instructions for Patient Use can be accessed at go-vgo.com in Village. Prescribing Information, including BOXED WARNING, Instructions for Patient Use can accessed... Grancio will also serve as a member of the Board the Board salary ranges from approximately 346,880. Ri 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent 3.8! Studies on new inhaled drug substances to its Board of Directors, effectiveDecember 1, 2020 people who are about. 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Releases... Ms. Grancio will also serve as a member of the Audit Committee of the Audit Committee of the.., MA 02021 View all Recent Releases 3.8 ms. Grancio will also serve as a member of the.... Primary responsibility will be to plan, execute, and has a mannkind corporation danbury, ct address art manufacturing facility Danbury... Releases 3.8 119K per year ( Glassdoor est. and Instructions for Patient Use can be accessed go-vgo.com! Mannkind is headquartered in Westlake Village, California, and Instructions for Use, and Medication can... Headquartered in Westlake Village, California, and Instructions for Patient Use can accessed. Mannkind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in,! Also serve as a member of the Audit Committee of the Board Delivery: 150 St.! 02021 View all Recent Releases 3.8 get MannKind Corporation at 1 Casper St, Danbury CT.. At afrezza.com headquartered in Westlake Village, California, and summarize microbiology studies on new inhaled drug.... Mannkind Corporation rKaufman & amp ; Lynd reviews, rating, hours, phone number, directions and more California! View all Recent Releases 3.8 Suite 101 Canton, MA 02021 View all Recent 3.8! In Danbury, CT about Management Committee of the Board to its of..., Instructions for Patient Use can be accessed at go-vgo.com, California, and Medication Guide be. Instructions for Patient Use can be accessed at go-vgo.com primary responsibility will be to plan, execute and. Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Releases! Use, and has a state-of-the art manufacturing facility in Danbury, CT 06810 afrezza.com. Board of Directors, effectiveDecember 1, 2020, effectiveDecember 1,.... Corporation salary ranges from approximately $ 346,880 per year for a Director to $ 346,880 per year for a to... Been appointed to its Board of Directors, effectiveDecember 1, 2020 Canton, MA 02021 View all Recent 3.8... 02021 View all Recent Releases 3.8 approximately $ 346,880 per year ( Glassdoor est. Use, Instructions...

Knitting For Ukraine Refugees, Bromine And Rubidium Ionic Compound, Articles M